Clinical characteristics and treatment evaluation of diffuse large B-cell lymphoma in Chinese children and adolescents: a multicenter clinical study of China-Net childhood lymphoma group B-NHL-2017.
Yang Fu, Ling Jin, Yanlong Duan, Jing Yang, Ying Liu, Bo Hu, Mincui Zheng, Yunpeng Dai, Ansheng Liu, Wei Liu, Leping Zhang, Fu Li, Baoxi Zhang, Xiaojun Yuan, Lirong Sun, Rong Liu, Zhuoyu Wen, Runming Jin, Shuquan Zhuang, Lian Jiang, Yufeng Liu, Haixia Zhou, Chen Shen, Hongsheng Wang, Yonghong Zhang, Xiaowen Zhai
{"title":"Clinical characteristics and treatment evaluation of diffuse large B-cell lymphoma in Chinese children and adolescents: a multicenter clinical study of China-Net childhood lymphoma group B-NHL-2017.","authors":"Yang Fu, Ling Jin, Yanlong Duan, Jing Yang, Ying Liu, Bo Hu, Mincui Zheng, Yunpeng Dai, Ansheng Liu, Wei Liu, Leping Zhang, Fu Li, Baoxi Zhang, Xiaojun Yuan, Lirong Sun, Rong Liu, Zhuoyu Wen, Runming Jin, Shuquan Zhuang, Lian Jiang, Yufeng Liu, Haixia Zhou, Chen Shen, Hongsheng Wang, Yonghong Zhang, Xiaowen Zhai","doi":"10.1007/s00432-025-06260-4","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>China-Net Childhood Lymphoma (CNCL) group B-NHL-2017 study is a prospective multi-center study in China, with the purpose of standardizing the diagnosis and treatment of childhood lymphoma, and improving the prognosis.</p><p><strong>Methods: </strong>From May 2017 to June 2023, 20 centers participated in the diffuse large B-cell lymphoma (DLBCL) study. The clinical data were analyzed to summarize the clinical characteristics, treatment response and outcome. The primary endpoint was 5-year event-free survival (EFS). The trial is registered with the Chinese Clinical Trial Registry (ChiCTR1800020067).</p><p><strong>Results: </strong>A total of 138 children and adolescents were enrolled, including 101 males and 37 females. The median age of disease diagnosis was 9.0 years (range: 2.3-15.5 years). The range of follow-up time was 17 d-6.0 years. A total of 12 events occurred in this study, including 7 deaths. of which 4 patients died of disease and chemotherapy comorbidities (severe infection, septic shock, etc.), 1 died of disease progression (enlargement of the primary tumor and tumor metastasis), 1 died of recurrence, and 1 died of severe pneumonia in the third year after completing all chemotherapy courses. Recurrence occurred in 6 (4.3%) patients at 14.9 months (range: 4.4-32.6 months) after initial treatment. The 5-year overall survival (OS) was 90.7 ± 5.0% and the 5-year EFS was 85.5 ± 5.4%. Based on Cox regression analysis, no Rituximab during treatment is an independent risk factor for mortality in patients with DLBCL.</p><p><strong>Conclusion: </strong>The efficacy of CNCL-B-NHL-2017 protocol in the treatment of DLBCL in children and adolescents is close to results of international studies.</p>","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"151 7","pages":"220"},"PeriodicalIF":2.8000,"publicationDate":"2025-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12283495/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Cancer Research and Clinical Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00432-025-06260-4","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background: China-Net Childhood Lymphoma (CNCL) group B-NHL-2017 study is a prospective multi-center study in China, with the purpose of standardizing the diagnosis and treatment of childhood lymphoma, and improving the prognosis.
Methods: From May 2017 to June 2023, 20 centers participated in the diffuse large B-cell lymphoma (DLBCL) study. The clinical data were analyzed to summarize the clinical characteristics, treatment response and outcome. The primary endpoint was 5-year event-free survival (EFS). The trial is registered with the Chinese Clinical Trial Registry (ChiCTR1800020067).
Results: A total of 138 children and adolescents were enrolled, including 101 males and 37 females. The median age of disease diagnosis was 9.0 years (range: 2.3-15.5 years). The range of follow-up time was 17 d-6.0 years. A total of 12 events occurred in this study, including 7 deaths. of which 4 patients died of disease and chemotherapy comorbidities (severe infection, septic shock, etc.), 1 died of disease progression (enlargement of the primary tumor and tumor metastasis), 1 died of recurrence, and 1 died of severe pneumonia in the third year after completing all chemotherapy courses. Recurrence occurred in 6 (4.3%) patients at 14.9 months (range: 4.4-32.6 months) after initial treatment. The 5-year overall survival (OS) was 90.7 ± 5.0% and the 5-year EFS was 85.5 ± 5.4%. Based on Cox regression analysis, no Rituximab during treatment is an independent risk factor for mortality in patients with DLBCL.
Conclusion: The efficacy of CNCL-B-NHL-2017 protocol in the treatment of DLBCL in children and adolescents is close to results of international studies.
期刊介绍：
The "Journal of Cancer Research and Clinical Oncology" publishes significant and up-to-date articles within the fields of experimental and clinical oncology. The journal, which is chiefly devoted to Original papers, also includes Reviews as well as Editorials and Guest editorials on current, controversial topics. The section Letters to the editors provides a forum for a rapid exchange of comments and information concerning previously published papers and topics of current interest. Meeting reports provide current information on the latest results presented at important congresses.
The following fields are covered: carcinogenesis - etiology, mechanisms; molecular biology; recent developments in tumor therapy; general diagnosis; laboratory diagnosis; diagnostic and experimental pathology; oncologic surgery; and epidemiology.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
